Education
About Us
Working with TipRanks
Follow Us
Novonesis A/S - Adr (NVZMY)
:NVZMY
NVZMY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$54.26 - $72.19
Previous CloseN/A
Volume8.66K
Average Volume (3M)29.31K
Market Cap
$28.27B
Enterprise ValueN/A
Total Cash (Recent Filing)kr280.00M
Total Debt (Recent Filing)kr1.80B
Price to Earnings (P/E)85.5
Beta0.42
Next Earnings
May 08, 2025EPS Estimate
0.42Last Dividend Ex-Date
Apr 07, 2025Dividend Yield0.92%
Share Statistics
EPS (TTM)0.71
Shares Outstanding414,555,050
10 Day Avg. Volume58,329
30 Day Avg. Volume29,310
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.90
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Novonesis News
PremiumCompany Announcements
Novozymes A/S Highlights Strong Growth in Earnings Call
PremiumCompany Announcements
Novozymes A/S Reports Strong 2024 Growth and Positive 2025 Outlook
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
<0.01% Other Institutional Investors
99.99% Public Companies and
Individual Investors
NVZMY FAQ
What was Novonesis A/S - Adr’s price range in the past 12 months?
Novonesis A/S - Adr lowest stock price was $54.26 and its highest was $72.19 in the past 12 months.
What is Novonesis A/S - Adr’s market cap?
Novonesis A/S - Adr’s market cap is $28.27B.
When is Novonesis A/S - Adr’s upcoming earnings report date?
Novonesis A/S - Adr’s upcoming earnings report date is May 08, 2025 which is in 23 days.
How were Novonesis A/S - Adr’s earnings last quarter?
Novonesis A/S - Adr released its earnings results on Feb 26, 2025. The company reported $0.672 earnings per share for the quarter, beating the consensus estimate of $0.541 by $0.131.
Is Novonesis A/S - Adr overvalued?
According to Wall Street analysts Novonesis A/S - Adr’s price is currently Overvalued.
Does Novonesis A/S - Adr pay dividends?
Novonesis A/S - Adr pays a Semiannually dividend of $0.727 which represents an annual dividend yield of 0.92%. See more information on Novonesis A/S - Adr dividends here
What is Novonesis A/S - Adr’s EPS estimate?
Novonesis A/S - Adr’s EPS estimate is 0.42.
How many shares outstanding does Novonesis A/S - Adr have?
Novonesis A/S - Adr has 414,555,050 shares outstanding.
What happened to Novonesis A/S - Adr’s price movement after its last earnings report?
Novonesis A/S - Adr reported an EPS of $0.672 in its last earnings report, beating expectations of $0.541. Following the earnings report the stock price went up 5.771%.
Which hedge fund is a major shareholder of Novonesis A/S - Adr?
Currently, no hedge funds are holding shares in NVZMY
---
Novonesis Stock Smart Score
Company Description
Novonesis A/S - Adr
Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Europe, the Middle East, Africa, North America, the Asia Pacific, and Latin America. The company offers baking, beverages, dairy, starch, and protein solutions for the food and beverage industry; laundry, dishwashing, and professional cleaning solutions for the household care industry; agriculture solutions, including crop production, and animal health and nutrition solutions; bioyield and biocontrol solutions for crops; and grain and technical processing solutions, as well as bio energy solutions for liquefaction, saccharifaction, fermentation, fiber conversion, and biomass conversion. It also provides textile solutions, such as biopreparation, biopolishing, bleach clean-up, denim abrasion and finishing, and desizing solutions. In addition, the company offers solutions for pulp & paper, including fiber modification, bleach boosting, deposit control, starch modification, and deinking; leather solutions comprising acid bating, area expansion, bating, degreasing, soaking, and unhairing and liming; and water and waste management solutions, which consist of bioaugmentation, biogas, and sludge management. Further, it provides pharmaceutical solutions, including lipases, immobilized lipases, and proteases for biocatalysis, as well as rTrypsin for cell culture; and human health and protein solutions. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
---
NVZMY Company Deck
---
NVZMY Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong organic growth, improved profitability, successful integration, and sustainability achievements. However, challenges in the Human Health segment, particularly in the U.S. and China, and the impact of exiting certain markets were noted. Despite these challenges, the overall outlook for 2025 remains positive.Read More>---
NVZMY Revenue Breakdown
28.53% Household Care
24.83% Bioenergy
22.07% Food, Beverages & Human Health
12.82% Grain & Tech Processing
11.75% Agriculture & Animal Health
---
NVZMY Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Eastman Chemical
―
LyondellBasell
―
PPG Industries
―
RPM International
―
DuPont de Nemours
―
Best Analysts Covering NVZMY
1 Year
1 Year Success Rate
1/1 ratings generated profit
1 Year Average Return
+11.60%
reiterated a buy rating a year ago
Copying Cezara Lozneanu's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +11.60% per trade.
---